



ASX Announcement

Dapsone 7.5%, Gel launch in the United States

Melbourne, Australia; 9 May 2025; Acrux Limited (ASX ACR)

Acrux and its commercial partner TruPharma are pleased to announce the launch of Dapsone 7.5%, Gel in the United States.

Dapsone 7.5%, Gel is a prescription medicine used on your skin (topical) to treat acne vulgaris in children 9 years of age or older.

The product will be marketed in a tube presentation, positively differentiating it from all of its direct competitors which are available in pump bottle packaging.

Advantageously, the Acrux finished product is manufactured and packaged in the United States.

The FDA approved the Acrux product in both the differentiated tube and the bottle pump pack presentations. Acrux and its commercial partner TruPharma have chosen to launch the tube presentation, differentiating the product in a constructive manner for patients. The product will be launched in both the 60 gram and 90 gram presentations, which is consistent with competitor pack sizes in the market.

In the United States, IQVIA reports annual sales for the 12 months ending December 2024 generated by the branded product and its generic competitors (with which Acrux's product will compete) exceeding USD\$43 million and 171,000 packs.

Acrux CEO and Managing Director, Michael Kotsanis said:

“We are very excited to launch this differentiated product which has been developed in house by the Acrux R&D team.

Our scientists believe that our tube presentation is more convenient and easier to use than the alternative marketed products that are available in a bottle pump pack. It contains less plastic, leading to less waste and is less intensive to manufacture than a bottle pump pack. Tube presentations are far more widely used across broad consumer, over the counter and prescription categories of products, compared to bottle pump packaging.

This launch is in addition to the Dapsone 5%, Gel product launched in 2024.

The launch further demonstrates the capability of the Acrux team to execute the Company's strategy to develop and commercialise our pipeline of topically applied prescription pharmaceutical products.”



Authorised by the Board of Directors.

For more information, please contact

Michael Kotsanis
Acrux Limited
CEO & Managing Director
P: + 61 3 8379 0100
E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit www.acrux.com.au

About TruPharma

TruPharma, LLC is a front-end pharma sales and marketing company focused on commercializing branded and generic prescription drugs for the U.S. Market. TruPharma has a diverse portfolio of products distributed across multiple channels. TruPharma is operated by a team of experienced executives focused on getting complex products FDA-approved and into the market. For more Information: www.trupharma.com